359 related articles for article (PubMed ID: 25756299)
1. Cucurbitacin D Is a Disruptor of the HSP90 Chaperone Machinery.
Hall JA; Seedarala S; Rice N; Kopel L; Halaweish F; Blagg BS
J Nat Prod; 2015 Apr; 78(4):873-9. PubMed ID: 25756299
[TBL] [Abstract][Full Text] [Related]
2. Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex.
Stravopodis DJ; Margaritis LH; Voutsinas GE
Curr Med Chem; 2007; 14(29):3122-38. PubMed ID: 18220746
[TBL] [Abstract][Full Text] [Related]
3. Client Proteins and Small Molecule Inhibitors Display Distinct Binding Preferences for Constitutive and Stress-Induced HSP90 Isoforms and Their Conformationally Restricted Mutants.
Prince TL; Kijima T; Tatokoro M; Lee S; Tsutsumi S; Yim K; Rivas C; Alarcon S; Schwartz H; Khamit-Kush K; Scroggins BT; Beebe K; Trepel JB; Neckers L
PLoS One; 2015; 10(10):e0141786. PubMed ID: 26517842
[TBL] [Abstract][Full Text] [Related]
4. Discovery and development of heat shock protein 90 inhibitors as anticancer agents: a review of patented potent geldanamycin derivatives.
Kim T; Keum G; Pae AN
Expert Opin Ther Pat; 2013 Aug; 23(8):919-43. PubMed ID: 23641970
[TBL] [Abstract][Full Text] [Related]
5. Heat Shock Protein 90 Inhibitors: An Update on Achievements, Challenges, and Future Directions.
Li L; Wang L; You QD; Xu XL
J Med Chem; 2020 Mar; 63(5):1798-1822. PubMed ID: 31663736
[TBL] [Abstract][Full Text] [Related]
6. Blocking the chaperone kinome pathway: mechanistic insights into a novel dual inhibition approach for supra-additive suppression of malignant tumors.
Grover A; Shandilya A; Agrawal V; Pratik P; Bhasme D; Bisaria VS; Sundar D
Biochem Biophys Res Commun; 2011 Jan; 404(1):498-503. PubMed ID: 21144839
[TBL] [Abstract][Full Text] [Related]
7. Cruentaren A binds F1F0 ATP synthase to modulate the Hsp90 protein folding machinery.
Hall JA; Kusuma BR; Brandt GE; Blagg BS
ACS Chem Biol; 2014 Apr; 9(4):976-85. PubMed ID: 24450340
[TBL] [Abstract][Full Text] [Related]
8. Heat-shock protein 90 inhibitors in cancer therapy: 17AAG and beyond.
Georgakis GV; Younes A
Future Oncol; 2005 Apr; 1(2):273-81. PubMed ID: 16555999
[TBL] [Abstract][Full Text] [Related]
9. Alternative approaches to Hsp90 modulation for the treatment of cancer.
Hall JA; Forsberg LK; Blagg BS
Future Med Chem; 2014 Sep; 6(14):1587-605. PubMed ID: 25367392
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and structure--activity relationships for chimeric inhibitors of Hsp90.
Shen G; Wang M; Welch TR; Blagg BS
J Org Chem; 2006 Sep; 71(20):7618-31. PubMed ID: 16995666
[TBL] [Abstract][Full Text] [Related]
11. Novobiocin induces a distinct conformation of Hsp90 and alters Hsp90-cochaperone-client interactions.
Yun BG; Huang W; Leach N; Hartson SD; Matts RL
Biochemistry; 2004 Jun; 43(25):8217-29. PubMed ID: 15209518
[TBL] [Abstract][Full Text] [Related]
12. Hsp90 inhibitors: small molecules that transform the Hsp90 protein folding machinery into a catalyst for protein degradation.
Blagg BS; Kerr TD
Med Res Rev; 2006 May; 26(3):310-38. PubMed ID: 16385472
[TBL] [Abstract][Full Text] [Related]
13. The small-molecule kinase inhibitor D11 counteracts 17-AAG-mediated up-regulation of HSP70 in brain cancer cells.
Schaefer S; Svenstrup TH; Guerra B
PLoS One; 2017; 12(5):e0177706. PubMed ID: 28542269
[TBL] [Abstract][Full Text] [Related]
14. Alterations of the Hsp70/Hsp90 chaperone and the HOP/CHIP co-chaperone system in cancer.
Ruckova E; Muller P; Nenutil R; Vojtesek B
Cell Mol Biol Lett; 2012 Sep; 17(3):446-58. PubMed ID: 22669480
[TBL] [Abstract][Full Text] [Related]
15. Targeting the Hsp90-Cdc37-client protein interaction to disrupt Hsp90 chaperone machinery.
Li T; Jiang HL; Tong YG; Lu JJ
J Hematol Oncol; 2018 Apr; 11(1):59. PubMed ID: 29699578
[TBL] [Abstract][Full Text] [Related]
16. Geldanamycin, radicicol, and chimeric inhibitors of the Hsp90 N-terminal ATP binding site.
Hadden MK; Lubbers DJ; Blagg BS
Curr Top Med Chem; 2006; 6(11):1173-82. PubMed ID: 16842154
[TBL] [Abstract][Full Text] [Related]
17. N-terminal and C-terminal modulation of Hsp90 produce dissimilar phenotypes.
Wang Y; McAlpine SR
Chem Commun (Camb); 2015 Jan; 51(8):1410-3. PubMed ID: 25333923
[TBL] [Abstract][Full Text] [Related]
18. Discovery and validation of small-molecule heat-shock protein 90 inhibitors through multimodality molecular imaging in living subjects.
Chan CT; Reeves RE; Geller R; Yaghoubi SS; Hoehne A; Solow-Cordero DE; Chiosis G; Massoud TF; Paulmurugan R; Gambhir SS
Proc Natl Acad Sci U S A; 2012 Sep; 109(37):E2476-85. PubMed ID: 22895790
[TBL] [Abstract][Full Text] [Related]
19. Binding of immunophilins to the 90 kDa heat shock protein (hsp90) via a tetratricopeptide repeat domain is a conserved protein interaction in plants.
Owens-Grillo JK; Stancato LF; Hoffmann K; Pratt WB; Krishna P
Biochemistry; 1996 Dec; 35(48):15249-55. PubMed ID: 8952474
[TBL] [Abstract][Full Text] [Related]
20. Hsp90: Friends, clients and natural foes.
Verma S; Goyal S; Jamal S; Singh A; Grover A
Biochimie; 2016 Aug; 127():227-40. PubMed ID: 27295069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]